YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 11, 2011, Pages 1369-1380

  Rath, Timo ^a   Roderfeld, Martin ^a   Gler, Can ^b   Wenzel, Christian ^a   Graf, Jrgen ^c,d   Beitinger, Frigga ^b   Roeb, Elke ^a   Zachoval, Reinhart ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Deutsche Lufthansa AG   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Biological markers; extracellular matrix; fibrosis; hepatitis C; liver cirrhosis; matrix metalloproteinases; transient elastography

Indexed keywords

BIOLOGICAL MARKER; GELATINASE B; HYALURONIC ACID; LAMININ; PROCOLLAGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; YKL 40;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ELASTOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MALE; POPULATION; PRIORITY JOURNAL; TRANSIENT ELASTROGRAHPY;

ADIPOKINES; ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; HYALURONIC ACID; LAMININ; LECTINS; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; ROC CURVE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 80054052775     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2011.613949     Document Type: Article

References (65)

1. Brenner DA. Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 2009;120:361-8.
2. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84.
3. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-71.
4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39.
5. Castera L, Negre I, Samii K, Buffet C. Pain experienced during percutaneous liver biopsy. Hepatology 1999;30: 1529-30.
6. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: Results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000;32:477-81.
7. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500.
8. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-18.
9. Colloredo G, Guido M, Sonzogni, A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease. J Hepatol 2003;39:239-44.
10. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38: 1449-57.
11. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128: 343-50.
12. Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: Systematic review and metaanalysis. Clin Gastroenterol Hepatol 2007;5:1214-20.
13. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: A meta-analysis. Gastroenterology 2008;134:960-74.
14. Gressner AM, Gao CF, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenic process in liver: A short survey. World J Gastroenterol 2009;15:2433-40.
15. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology 2008;48:418-31.
16. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-20.
17. Sandrin L, Tanter M, Gennisson JL, Catheline S, Fink M. Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control 2002;49:436-46.
18. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-13.
19. Saito H, Tada S, Nakamoto N, Kitamura K, Horikawa H, Kurita S, et al. Efficacy of non-invasive elastometry on staging of hepatic fibrosis. Hepatol Res 2004;29:97-103.
20. Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: Correlation with serum markers of fibrosis. Hepatology 2006;43:771-9.
21. Hu B, Trinh K, Figueira WF, Price PA. Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J Biol Chem 1996;271:19415-20.
22. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006;53:172-209.
23. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 2002;365: 119-26.
24. De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 2001;285: 926-31.
25. Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005;11:476-81.
26. Mehta P, Ploutz-Snyder R, Nandi J, Rawlins SR, Sanderson SO, Levine RA. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2008;103:928-36.
27. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008;47:789-98.
28. Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, et al. Serum fibrosis markers are associated with liver disease progression in nonresponder patients with chronic hepatitis C. Gut 2010;59: 1401-9.
29. Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Medina-Pestana JO, Lanzoni VP, Ferraz ML, et al. YKL-40- and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection. Scand J Gastroenterol 2010;45:615-22.
30. Berres ML, Papen S, Pauels K, Schmitz P, Zaldivar MM, Hellerbrand C, et al. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol 2009;50: 370-6.
31. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001;21:311-35.
32. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 1997;242: 27-33.
33. Guechot J, Loria A, Serfaty L, Giral P, Giboudeau J, Poupon R. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: Effect of alpha-interferon therapy. J Hepatol 1995;22:22-6.
34. Lydatakis H, Hager IP, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int 2006;26:864-71.
35. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005;25:779-86.
36. Guechot J, Serfaty L, Bonnand AM, Chazouilleres O, Poupon RE, Poupon R. Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol 2000;32:447-52.
37. Xie SB, Yao JL, Zheng RQ, Peng XM, Gao ZL. Serum hyaluronic acid, procollagen type III and IV in histological diagnosis of liver fibrosis. Hepatobiliary Pancreat Dis Int 2003;2:69-72.
38. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997;113:1609-16.
39. McHutchison JG, Blatt LM, De Medina M, Craig JR, Conrad A, Schiff ER, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000;15:945-51.
40. Halfon P, Bourliere M, Penaranda G, Deydier R, Renou C, Botta-Fridlund D, et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005;4:6.
41. Plebani M, Burlina A. Biochemical markers of hepatic fibrosis. Clin Biochem 1991;24:219-39.
42. Sato S, Nouchi T, Worner TM, Lieber CS. Liver fibrosis in alcoholics. Detection by Fab radioimmunoassay of serum procollagen III peptides. JAMA 1986;256:1471-3.
43. Nakatsukasa H, Nagy P, Evarts RP, Hsia CC, Marsden E, Thorgeirsson SS. Cellular distribution of transforming growth factor-beta 1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. J Clin Invest 1990;85:1833-43.
44. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328:1828-35.
45. Schuppan D. Connective tissue polypeptides in serum as parameters to monitor antifibrotic treatment in hepatic fibrogenesis. J Hepatol 1991;13(Suppl 3):S17-25.
46. Roderfeld M, Rath T, Voswinckel R, Dierkes C, Dietrich H, Zahner D, et al. Bone marrow transplantation demonstrates medullar origin of CD34+ fibrocytes and ameliorates hepatic fibrosis in Abcb4-/- mice. Hepatology 2010;51: 267-76.
47. Lichtinghagen R, BahrMJ. Noninvasive diagnosis of fibrosis in chronic liver disease. Expert Rev Mol Diagn 2004;4:715-26.
48. Kropf J, Gressner AM, Negwer A. Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases. Clin Chem 1988;34:2026-30.
49. KropfJ, GressnerAM,TittorW.Logistic-regressionmodelfor assessing portal hypertension by measuring hyaluronic acid (hyaluronan)andlaminin in serum.ClinChem1991;37:30-5.
50. Gressner AM, Tittor W, Kropf J. The predictive value of serum laminin for portal hypertension in chronic liver diseases. Hepatogastroenterology 1988;35:95-100.
51. Kondo M, Miszputen SJ, Leite-mor MM, Parise ER. The predictive value of serum laminin for the risk of variceal bleeding related to portal pressure levels. Hepatogastroenterology 1995;42:542-5.
52. Bahr MJ, Boker KH, Horn W, Gunzler V, Manns MP. Serum laminin P1 levels do not reflect critically elevated portal pressure in patients with liver cirrhosis. Hepatogastroenterology 1997;44:1200-5.
53. Fabris P, Marranconi F, Bozzola L, Biasin MR, De Lazzari F, Plebani M, et al. Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN. J Gastroenterol 1999;34:345-50.
54. Roeb E, Rose-John S, Erren A, Edwards DR, Matern S, Graeve L, et al. Tissue inhibitor of metalloproteinases-2 (TIMP-2) in rat liver cells is increased by lipopolysaccharide and prostaglandin E2. FEBS Lett 1995;357:33-6.
55. Roeb E, Graeve L, Mullberg J, Matern S, Rose-John S. TIMP-1 protein expression is stimulated by IL-1 beta and IL-6 in primary rat hepatocytes. FEBS Lett 1994;349: 45-9.
56. Roeb E, Graeve L, Hoffmann R, Decker K, Edwards DR, Heinrich PC. Regulation of tissue inhibitor of metalloproteinases-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures. Hepatology 1993;18:1437-42.
57. Roeb E, Purucker E, Breuer B, Nguyen H, Heinrich PC, Rose-John S, et al. TIMP expression in toxic and cholestatic liver injury in rat. J Hepatol 1997;27:535-44.
58. Iredale JP. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 1997;29:43-54.
59. Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJ. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996;110:821-31.
60. Yata Y, Takahara T, Furui K, Zhang LP, Jin B, Watanabe A. Spatial distribution of tissue inhibitor of metalloproteinase-1 mRNA in chronic liver disease. J Hepatol 1999;30:425-32.
61. Lichtinghagen R, Bahr MJ, Wehmeier M, Michels D, Haberkorn CI, Arndt B, et al. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci (Lond) 2003;105:373-82.
62. Boker KH, Pehle B, Steinmetz C, Breitenstein K, Bahr M, Lichtinghagen R. Tissue inhibitors of metalloproteinases in liver and serum/plasma in chronic active hepatitis C and HCV-induced cirrhosis. Hepatogastroenterology 2000;47: 812-19.
63. Reif S, Somech R, Brazovski E, Reich R, Belson A, Konikoff FM, et al. Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chronic hepatitis C. Digestion 2005;71:124-30.
64. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373-81.
65. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-73.